Bristol, Prime Medicine in deal to develop T-cell therapies
Prime Medicine and Bristol Myers Squibb are collaborating on next-generation ex vivo T-cell therapies. Read more here.
Pharmaceutical Technology4h
Modalis wins FDA rare paediatric designation for CMD CRISPR therapy
Modalis Therapeutics has been awarded a rare paediatric disease designation by the US Food and Drug Administration (FDA) for ...
FDA approves PureTech’s KarXT to treat schizophrenia in adults
PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...
Pharmaceutical Technology10h
SK pharmteco announces $260m production expansion in South Korea
SK pharmteco, a contract development and manufacturing organisation, has announced an investment of $260m to expand its small ...